Jeremy Veenstra-VanderWeele uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism.
Jeremy Veenstra-VanderWeele
From this contributor
Why serotonin medications may yet help children with autism
A class of medications used to treat obsessive-compulsive disorder seems to ease compulsive behaviors in adults with autism. Why can't we tell if these medications work similarly in children with the condition?
Why serotonin medications may yet help children with autism
How to evaluate new medications for autism
There are no available medications for treating autism’s core symptoms, but there are several candidates in clinical trials. Jeremy Veenstra-VanderWeele describes the factors researchers must take into account when developing drugs for the disorder.
How to evaluate new medications for autism
Explore more from The Transmitter
What leeches reveal about movement
Lidia Szczupak turned to the animals to explore how the nervous system coordinates movement.
What leeches reveal about movement
Lidia Szczupak turned to the animals to explore how the nervous system coordinates movement.
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Redefining underrepresentation in global neuroscience
Shifting the focus of equity initiatives from identity categories to structural barriers can reveal overlooked challenges and increase support and participation worldwide.
Scientific talent is global. Access to the world’s scientific stage is not.
Neuroscience in Chile, and across Latin America, does not lack talent or ideas, but the systems that make science visible—prestigious journals, conferences and networks—increasingly price its researchers out.
Scientific talent is global. Access to the world’s scientific stage is not.
Neuroscience in Chile, and across Latin America, does not lack talent or ideas, but the systems that make science visible—prestigious journals, conferences and networks—increasingly price its researchers out.